Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 16/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4488184 | 0.88 | SCN9A (0.53) | SCN9ATRPA1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL1400156 | 0.85 | SCN9A (0.60) | SCN9ATRPA1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL4492897 | 0.82 | SCN9A (0.54) | SCN9ATRPA1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL4500439 | 0.82 | SCN9A (0.51) | SCN9ATRPA1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL4482849 | 0.82 | SCN9A (0.59) | SCN9ATRPA1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL4492039 | 0.81 | SCN9A (0.57) | SCN9ATRPA1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL4484208 | 0.80 | SCN9A (0.54) | SCN9ATRPA1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL1400166 | 0.80 | SCN9A (0.65) | SCN9ACYP2C9CYP3A4CYP2D6SCN10A | |
| SCHEMBL4489498 | 0.80 | SCN9A (0.52) | SCN9ATRPA1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL4498464 | 0.80 | SCN9A (0.56) | SCN9ATRPA1CYP2C9CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572822-B2 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572822-B2 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572822-B2 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1606269-B1 | BIARYL SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK & CO INC (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1606269-B1 | BIARYL SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK & CO INC (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080171777-A1 | Biaryl substituted triazoles as sodium channel blockers | MERCK SHARP & DOHME LLC | 2008-07-17 | — | — | US | disclosed |
| US-20080171777-A1 | Biaryl substituted triazoles as sodium channel blockers | MERCK SHARP & DOHME LLC | 2008-07-17 | — | — | US | disclosed |
| US-20080171777-A1 | Biaryl substituted triazoles as sodium channel blockers | MERCK SHARP & DOHME LLC | 2008-07-17 | — | — | US | disclosed |
| US-7326726-B2 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO., INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326726-B2 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO., INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326726-B2 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO., INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-20060183897-A1 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO., INC. | 2006-08-17 | — | — | US | disclosed |
| US-20050119261-A1 | Biaryl substituted triazoles as sodium channnel blockers | MERCK SHARP & DOHME LLC | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171777-A1 | Biaryl substituted triazoles as sodium channel blockers | SCN3A, TRPV1, SCN1B | SCN9A 56/4885TRPA1 10/4885CYP2C9 349/4885 |
| US-20050119261-A1 | Biaryl substituted triazoles as sodium channnel blockers | SCN3A, TRPV1, KCNN3 | SCN9A 67/4885TRPA1 8/4885CYP2C9 279/4885 |
| US-20060183897-A1 | Biaryl substituted triazoles as sodium channel blockers | SCN3A, TRPV1, SCN1B | SCN9A 56/4885TRPA1 10/4885CYP2C9 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.